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        The incidence of type 1 diabetes among chil-
dren and adolescents has increased markedly in 
the Western countries during the recent de-
cades (  1  ). The incidence has reached record 
levels in Finland, where, currently, 1/120 chil-
dren develops type 1 diabetes before the age of 
15 yr (  2  ). The annual incidence, which showed 
a linear steady increase from 1965 to 1996 (  3  ), 
was recently found to be increasing even faster 
than before, with the number of cases diag-
nosed at or before 14 yr of age expected to 
double in the next 15 yr (  4  ). Although     70% 
of subjects with type 1 diabetes carry defi  ned 
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  The risk determinants of type 1 diabetes, initiators of autoimmune response, mechanisms 
regulating progress toward      cell failure, and factors determining time of presentation of 
clinical diabetes are poorly understood. We investigated changes in the serum metabolome 
prospectively in children who later progressed to type 1 diabetes. Serum metabolite profi  les 
were compared between sample series drawn from 56 children who progressed to type 
1 diabetes and 73 controls who remained nondiabetic and permanently autoantibody nega-
tive. Individuals who developed diabetes had reduced serum levels of succinic acid and 
phosphatidylcholine (PC) at birth, reduced levels of triglycerides and antioxidant ether 
phospholipids throughout the follow up, and increased levels of proinfl  ammatory lysoPCs 
several months before seroconversion to autoantibody positivity. The lipid changes were not 
attributable to HLA-associated genetic risk. The appearance of insulin and glutamic acid 
decarboxylase autoantibodies was preceded by diminished ketoleucine and elevated glu-
tamic acid. The metabolic profi  le was partially normalized after the seroconversion. Auto-
immunity may thus be a relatively late response to the early metabolic disturbances. 
Recognition of these preautoimmune alterations may aid in studies of disease pathogenesis 
and may open a time window for novel type 1 diabetes prevention strategies. 
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tion–Noncommercial–Share Alike–No Mirror Sites license for the fi  rst six months 
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mercial–Share Alike 3.0 Unported license, as described at http://creativecommons
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  To compare the fi  ndings in the genetically defi  ned DIPP 
cohort to those in another cohort of children that was not 
genetically defi  ned, the metabolomes of another six children 
in the Special Turku Coronary Risk Factor Intervention 
Project for Children (STRIP) (  12  ) who had developed type 1 
diabetes were investigated before disease presentation and 
compared with their six age- and sex-matched nondiabetic 
controls from the same study. The STRIP series also com-
prised 87 samples, which had been collected annually be-
tween the ages of 7 mo and 5  –  15 yr. Three of the children 
who developed diabetes turned out to carry the defi  ned 
HLA-DQB1 risk alleles, but all had had multiple diabetes-
associated autoanti  bodies for 2  –  13 yr before the presentation 
risk-associated genotypes at the HLA locus, only 3  –  7% of the 
carriers of such genetic risk markers develop the disease (  5  ). 
  Seroconversion to islet autoantibody positivity has been 
the fi  rst detectable signal for the onset of autoimmunity and 
progression toward diabetes. Although seroconversion usually 
precedes the clinical disease by months to years, its occur-
rence may already be too late for therapeutic approaches 
aimed at preventing progression to overt diabetes. As long as 
the initiators of the autoimmune response remain unknown 
and the mechanisms supporting progression toward      cell 
failure are poorly understood, the estimation of the absolute 
disease risk and time of disease presentation in genetically 
susceptible individuals and the discovery of eff  ective preven-
tion remain a challenge. 
  In 1994, an ongoing birth cohort study (Type 1 Diabetes 
prediction and prevention study [DIPP]) was launched in 
Finland (  6  ). After informed parental consent, HLA alleles associ-
ated with type 1 diabetes risk or protection were analyzed from 
cord blood, and subjects carrying risk-associated genotypes 
were followed over time to establish the time point of sero-
conversion and diabetes development. Over a period of 11.5 yr 
until 2006,   >  100,000 newborn infants have been screened for 
genetic risk and   >  8,000 at-risk children are being followed. 
  Metabolomics systematically studies the chemical fi  nger-
prints in cells, tissues, and biofl  uids in a given physiological 
and environmental context. New analytical methods combined 
with bioinformatics provide a way to measure the extended 
metabolome (  7  ). The metabolic phenotype is sensitive to 
subtle but pathogenically relevant factors such as age, lifestyle, 
nutrition, and the microbe environment of the gut (  8  –  10  ). 
Changes in the concentrations of metabolites during early 
development may thus refl  ect both genetic and environmental 
factors infl  uencing later susceptibility to chronic diseases (  11  ). 
  In this paper, we hypothesize that alterations in the meta-
bolic phenotypes characterize the early pathogenesis of type 
1 diabetes. We apply the metabolomics strategy to the unique 
preautoimmune and prediabetic sample series collected in 
DIPP and provide evidence that metabolic disturbances pre-
cede the autoimmunity that is characteristically observed be-
fore development of type 1 diabetes. 
    RESULTS   
  Subjects 
  Serum metabolite profi  les were compared between 50 DIPP 
children who progressed to type 1 diabetes (the progressors) 
and 67 nonprogressors, who remained healthy and autoanti-
body negative and were matched with the progressors for 
time and site of birth, gender, and HLA risk group (  Fig. 1  ).   
The 117 DIPP children contributed 1,109 samples (9.5 sam-
ples per child on average) covering the time from 3 mo of age 
to clinical diabetes in the progressors. Additionally, the cord 
blood samples of 39 DIPP children from Turku, 15 of which 
progressed to diabetes before the age of 12 yr, were analyzed. 
Two progressors included in the cord blood series were also 
included in the longitudinal sample series. 
    Figure 1.         Subject selection fl  owchart for the metabolomics study.  
Nonprogressors were matched with progressors for time and site of birth, 
gender, and HLA risk group. Status of DIPP (  6  ) and STRIP (  12  ) studies as of 
June 6, 2006.     JEM VOL. 205, December 22, 2008 
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phosphatidylcholine (PC), as well as high lysoPC and leucine 
(  Fig. 2 B  ). This period was also accompanied by abnormally 
high glutamic acid and     -aminobutyric acid (GABA), as well 
as low glutamine and     -ketoglutarate (  Fig. 2 C  ). During glu-
tamic acid decarboxylase antibody (GADA) positivity, these 
metabolite concentrations almost normalized, whereas ala-
nine diminished and 2-hydroxybutyric acid increased tran-
siently (unpublished data). 
  Metabolome in prospective sample series and cord blood 
  The analysis of longitudinal series of serum metabolomes 
during the asymptomatic period from children who later de-
veloped diabetes revealed characteristic metabolite patterns 
that preceded or accompanied the initial seroconversion to 
autoantibody positivity (  Fig. 3  ).   Compared with children 
who remained autoantibody negative, the serum lipidome of 
progressors showed a consistent decrease in triglycerides (P = 
0.005) and multiple phospholipids, including ether PCs (P   <   
0.001), PCs (P = 0.04), and sphingomyelins (P = 0.09), in 
samples obtained from infancy to early school years (  Fig. 3, 
A and B  ). The diff  erence in lipidome was observed before the 
autoantibodies appeared and it persisted throughout the en-
tire age range covered. Low phospholipid levels were also 
observed in cord blood, although only one of the lipids de-
tected in the longitudinal sample series diff  ered signifi  cantly 
between the progressors and nonprogressors. However, the 
total amount of cord serum PC was 1.22-fold decreased in 
the progressors (P = 0.004), as shown in Fig. S2 (available at 
http://www.jem.org/cgi/content/full/jem.20081800/DC1). 
  We also compared the lipid concentration diff  erences be-
tween the children at high and moderate HLA-associated gene-
tic risk of developing type 1 diabetes. No signifi  cant diff  erences 
between the genetic risk groups were identifi  ed among the 
progressors or the nonprogressors (Fig. S3, available at http://
www.jem.org/cgi/content/full/jem.20081800/DC1), thus 
of diabetes. Selected characteristics of the study subjects are 
shown in   Table I  .   
  Analytical platforms 
  Current lipidomics platforms constitute an effi   cient way to 
separate and quantify hundreds of lipid molecules (  13, 14  ). 
For this study, ultra performance liquid chromatography 
coupled to mass spectrometry was applied as previously des-
cribed (  8, 15  ). The fi   nal lipidomics dataset, not including 
the cord blood data, comprised 53 identifi  ed lipids mea-
sured in each of the 1,196 samples. A total of 515 samples 
were from progressors to type 1 diabetes, among which 
112 were collected before seroconversion to autoantibody 
positivity. In each of the 39 cord blood samples, 249 lipids 
were identifi  ed. Once the complete dataset was constructed, 
we fi  rst  confi   rmed that the samples were not aff  ected  by 
the time of storage (Fig. S1, available at http://www.jem
.org/cgi/content/full/jem.20081800/DC1). 
  Serum samples were also analyzed by two-dimensional 
gas chromatography coupled to time of fl  ight mass spectrom-
etry (GCxGC-TOF/MS). This analytical technology pro-
vides a broad profi  le of small molecules (  16  ). The analysis was 
performed on a random subset of DIPP study samples from 
Turku, comprising sample series from 13 progressors and 26 
matched nonprogressors. The fi   nal metabolomics dataset 
obtained by GCxGC-TOF/MS consisted of 75 identifi  ed 
metabolites measured in each of the 419 samples. 
  Case report 
  The interdependence of metabolic and immune system fac-
tors is fi  rst demonstrated in   Fig. 2   for a girl with an extended 
sample series available.   She developed overt type 1 diabetes 
close to 9 yr of age (  Fig. 2 A  ). The time before the appear-
ance of the fi  rst autoantibody was characterized by abnor-
mally low succinic acid (not depicted), ketoleucine, and ether 
    Table I.        Selected characteristics of the subjects included in the study. 
Progressors Nonprogressors
  Gender   (girls, boys) 31, 25 40, 33
  City of birth   (Turku, Oulu) 29, 27 45, 28
  Season at time of birtha              
  (winter, spring, summer, autumn)
11, 19, 14, 12 15, 25, 19, 14
  Season at time of diagnosis 
    (winter, spring, summer, autumn)
11, 21, 10, 13 NA
  Age at time of diagnosis   
  (median, range in months)
44, 6  –  162 NA
  Age at time of fi  rst seroconversion   
  (median, range in months)
12, 6  –  96 NA
  HLA risk haplotypes 
     Moderate risk    b     DR4-DQ8/x 
  (x = any haplotype except DR2-DQ6, DR5-DQ7 
or DR3-DQ2)
33 46
     High risk (DR3-DQ2/DR4-DQ8) 17 20
  a  Seasons are defi  ned as winter for December to February, spring for March to May, summer for June to August, and autumn for September to November.
  b  HLA genotype information is shown for the DIPP children only. One nonprogressor, not included in the table, had the moderate risk DR3-DQ2/x haplotype.2978 METABOLOME EN ROUTE TO TYPE 1 DIABETES   | Ore  š  ic  ˇ   et  al. 
confi  rming that the observed lipid changes are not attribut-
able to HLA-associated genetic risk. 
  One subclass of phospholipids that was repeatedly low in 
progressors and showed low within-person variability were 
ether PCs (  Fig. 3, A and B  ). Ethanolamine plasmalogen levels 
    Figure 2.         Selected autoantibody and metabolite changes during 
the prediabetic period in a girl who progressed to type 1 diabetes at 
close to 9 yr of age (HLA-haplotype DR7-DQ2/DR4-DQ8, moderate 
genetic risk).   (A) GADA and IAA profi  les. The relative autoantibody level 
values are calculated as the ratio of their measured levels and corre-
sponding cutoff limits for autoantibody positivity. Scales are linear and 
adjusted separately for each autoantibody for clarity. Time of seroconver-
sion to positivity for each autoantibody is marked, as is the time of diag-
nosis of type 1 diabetes. The child also seroconverted to ICA and IA-2A 
autoantibody positivity within 6 mo before the appearance of IAA. 
(B) Changes of ketoleucine, leucine, lysoPC (the profi  le shown is for the most 
abundant lysoPC species PC(18:0/0:0)), and ether PC (the profi  le shown is 
for the most abundant ether PC species PC(O-18:1/20:4)) with age. Fold 
changes are calculated as ratios of metabolite level at a given time point 
and the normal level, i.e., the mean value across all samples in the non-
progressors. Scales are linear and adjusted separately for each metabolite 
for clarity. (C) The changes of glutamic acid, GABA,    -ketoglutarate 
(    -KG), and glutamine with age.     
    Figure 3.         Serum lipidome in cord blood and prospective sample 
series.   (A) Differences in serum lipidome between the progressors to type 
1 diabetes and nonprogressors who remained autoantibody negative 
throughout the follow up. The age groups are divided into birth (cord 
blood) and then into groups covering 1-yr cohorts. Only one sample per 
subject, closest to the mean age within the time window, is used in each 
comparison. The number of subjects included in each age cohort is shown 
at the bottom. The last sample of each progressor was the sample drawn 
last before diagnosis of diabetes. (B) Total triglyceride and ether PC con-
centrations for the age cohorts shown in A calculated as the sum of lipid 
concentrations within each class. Both lipid classes were found consis-
tently down-regulated in the progressors, as tested by the linear mixed 
effects model for the overall trend throughout the follow up. The error 
bars show SEM. (C) Levels of the lysoPC PC(18:0/0:0) and the ether PC 
PC(O-18:1/20:4) at the age of 18 mo for DIPP children. The two lipids 
were up-regulated (P = 0.0009) and down-regulated (P = 0.04) in pro-
gressors, respectively. Only one measurement, closest to the age of 18 mo 
within the 12  –  24-mo age interval is shown for each subject. Subjects 
who already seroconverted to autoantibody positivity against one or mul-
tiple islet autoantigens are specifi  cally marked with different colors, 
whereas the subjects in moderate and high HLA-conferred risk groups, as 
defi  ned in   Table I  , are marked with circles and squares, respectively.     JEM VOL. 205, December 22, 2008 
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(P = 0.009) and 2.5-fold (P = 0.02) lower in the progressors 
than in the nonprogressors, respectively, whereas the BCAAs 
showed a rising trend before IAA emerged. 
  High glutamic acid values were associated with subse-
quent appearance of GADA and IAA. Glutamic acid was in-
creased between 4.1-fold (0  –  9 mo; P = 0.06) and 4.7-fold 
(9  –  18 mo; P = 0.03) before seroconversion to GADA positivity 
were also low in progressors (Fig. S4, available at http://
www.jem.org/cgi/content/full/jem.20081800/DC1). Con-
centration of the most abundant lysoPC, PC(18:0/0:0), was 
elevated in the progressors during the fi  rst 2 yr of life (  Fig. 3 A  ). 
During this period, concentrations of PC(18:0/0:0) and 
PC(O-18:1/20:4), together with most other ether phospho-
lipids, were inversely related (  Fig. 3 C  ). 
  Although no clear persistent changes were observed in 
small molecule profi  les using GCxGC-TOF/MS (  Fig. 4  ), 
succinic acid, a key metabolite of citric acid cycle, was diminis-
hed fourfold in progressors at birth and during the fi  rst year 
of life (P = 0.04), whereas the citric acid was 1.7-fold de-
creased at birth (P = 0.02).   
  Metabolic changes before emergence of islet autoantibodies 
and diagnosis of type 1 diabetes 
  To determine whether the metabolome abnormalities showed 
association with the emergence of islet autoantibodies, the 
metabolomes of the progressors and of the nonprogressors 
were compared using samples obtained from   ±  18 mo from 
the emergence of the fi  rst autoantibody (  Fig. 5 A  ).   The lyso PC 
PC(18:0/0:0) was increased 1.5-fold within 9  –  18 mo before 
seroconversion (P = 0.03) and 1.3-fold within the succeeding 
9 mo (P = 0.005;   Fig. 5 B  ). 
  Metabolomes in the progressors and nonprogressors showed 
several unexpected diff  erences around the time when auto-
antibodies appeared. Glutamic acid was 5.2-fold and 32-fold 
increased 9  –  18 mo (P = 0.02) and 0  –  9 mo before serocon-
version (P = 0.02), respectively. Branched chain amino acids 
(BCAAs) such as leucine and isoleucine were also increased 
before seroconversion, whereas ketoleucine concentration 
was diminished. 
  We also studied whether serum metabolome profi  les at 
the presentation of clinical diabetes resembled those seen be-
fore the fi  rst autoantibody species emerged. The profi  les in 
the progressors during the last visits before diagnosis of type 1 
diabetes revealed no clear diff  erences as compared with the 
profi  les of matched nonprogressors (Fig. S5, available at 
http://www.jem.org/cgi/content/full/jem.20081800/DC1), 
except for specifi  c phospholipids which were similarly diminis-
hed as they had been at an early age and around the time of 
seroconversion to autoantibody positivity. When we tested 
whether the concentrations of the key lipids found altered in 
progressors before autoimmunity correlated with the age at 
diagnosis or the time interval between the fi  rst seroconver-
sion to islet autoimmunity and diagnosis, no signifi  cant trends 
were found (Figs. S6 and S7). 
  Associations of metabolome with the appearance 
of specifi  c autoantibodies 
  The appearance of each autoantibody (insulin autoantibody 
[IAA], GADA, IA-2A, or islet cell autoantibody [ICA]) was 
preceded by a relative increase in the lysoPC PC(18:0/0:0) 
and followed by a transient two to fourfold elevation of 
2-hydroxybutyric acid (  Fig. 5 C  ). Within 9  –  18 mo and 0  –  9 
mo before the appearance of IAA, ketoleucine was 20-fold 
    Figure 4.         Comparison of serum metabolomes between progressors 
to type 1 diabetes and nonprogressors who remained autoantibody 
negative throughout the follow up.   The age groups are divided into 
birth (cord blood) and then into groups covering 1-yr periods of followup. 
Only one sample per subject, closest to the mean age within the time 
window (0.5, 1.5, 2.5 yr, etc.), is used in each comparison. Clustering was 
performed for the profi  les across all available samples (  n   = 419) using 
Ward linkage and the nonparametric Spearman rank correlation  –  based 
distance metric. The number of subjects included in each age cohort is 
shown at the bottom.     2980 METABOLOME EN ROUTE TO TYPE 1 DIABETES   | Ore  š  ic  ˇ   et  al. 
  We found that the children who developed type 1 diabe-
tes have reduced serum levels of succinic acid and PC at birth 
and reduced levels of multiple phospholipids and triglycerides 
throughout the follow up. As PC is a major source of choline 
in the body, our data suggest that the progressors are choline-
defi  cient since birth. Besides being an important epigenetic 
regulator (  17  ), choline also controls the secretion of triglyc-
eride-rich very low-density lipoprotein particles. Choline 
defi  ciency leads to lower serum triglyceride levels and their 
increased accumulation in liver (  18  ). This is consistent with 
our observation that during infancy and early childhood the 
progressors have low triglyceride levels. Although diminished 
choline values were observed in the progressors already at 
birth, nongenetic regulation cannot be excluded because, for 
example, choline metabolism is dependent on the composi-
tion of the intestinal microbiota (  19  ). Consistent with this, 
succinic acid, which is also diminished in the progressors at 
birth, is as well produced by the human intestinal microbiota 
(  20, 21  ). Interaction of gut microbiota with the innate im-
mune system is an important factor aff  ecting T1D predisposi-
tion in the nonobese diabetic mouse (  22  ). Accordingly, it is 
conceivable that maternal diet or intestinal fl  ora during preg-
nancy may aff  ect the choline and succinic acid levels in new-
born infants and thereby modify systemic energy metabolism 
and the immune system in the off  spring. 
  Our data show that ether PCs were consistently low in the 
progressors. The plasmalogens, which are the most abundant 
ether phospholipids in normal serum, protect cells from oxi-
dative damage (  23  ). Plasmalogen defi  ciency may also indicate 
that subjects who are genetically susceptible to type 1 diabetes 
are particularly prone to specifi  c metabolic stress, which not 
only leads to plasmalogen defi  ciency but also triggers progres-
sion toward diabetes. One potential pathway linking low 
and 8.4-fold (0  –  9 mo; P = 0.02) before seroconversion to 
IAA positivity. 
    DISCUSSION   
  In this longitudinal study, we compared serum metabolome in 
children who, during follow up, progressed to type 1 diabetes-
associated autoimmunity and, further, to clinical diabetes 
(progressors) or who remained permanently healthy and au-
toantibody negative. Our study strongly suggests that metabolic 
dysregulation precedes overt autoimmunity in type 1 diabetes. 
    Figure 5.         Selected metabolite differences between progressors and 
nonprogressors within 18-mo periods before and after seroconver-
sion to islet autoantibody positivity, divided into four 9-mo periods.  
(A) Illustrative matching of progressors and nonprogressors for studies of 
seroconversion-related changes in metabolome. For each progressor  ’  s 
samples near the selected period of seroconversion, the age-matched 
control samples were selected from the matched nonprogressor. 
(B) Changes before (Ab       ) and after (Ab  + )  fi  rst seroconversion to islet auto-
antibody positivity. Only one sample from each subject, closest to the time 
of seroconversion, is included within each time period. Clustering was 
performed as described in   Fig. 4  . (C) Changes before and after seroconver-
sion to positivity for each autoantibody. Only one sample from each sub-
ject, closest to the time of seroconversion, is included within each time 
period. Lipids were measured in 56 progressors and 73 nonprogressors, 
whereas the metabolites were measured in 13 progressors and 26 non-
progressors as shown in Table S1.     
    Figure 6.         Biochemical model of metabolic changes in progressors 
to type 1 diabetes prior and after seroconversion to islet autoim-
munity.   Detected changes of specifi  c metabolites of citric acid cycle and 
glutamic acid metabolism before (left boxes) and shortly after (right 
boxes) the appearance of GADA are shown.     JEM VOL. 205, December 22, 2008 
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spectively collected sample series, which covered the time 
from birth to overt type 1 diabetes. However, it is essential that 
these results are validated using other well characterized popu-
lation cohorts. The German BabyDiab (  36  ), the US-based 
DAISY (  37  ) and PANDA studies (  38  ), and the multinational 
TEDDY study (  39  ) will hopefully, in time, be able to confi  rm 
or reject our fi  ndings. To address the hypotheses derived from 
our fi  ndings and to understand the tissue-specifi  c mechanisms 
behind the early metabolic disturbances and associated autoim-
mune changes preceding the disease onset, experimental mod-
els refl  ecting both the metabolic and autoimmune components 
of early type 1 diabetes will have to be established. 
  In conclusion, dysregulation of metabolism precedes      
cell autoimmunity and overt type 1 diabetes. The factors 
leading to metabolic stress and autoimmune responses clearly 
need to be investigated in further studies in the context of 
autoimmune diseases in general. Our fi  ndings also imply that 
metabolic or immunomodulatory interventions during the 
preautoimmune period may be used as a potential strategy for 
prevention of type 1 diabetes. 
  MATERIALS AND METHODS 
  DIPP study.     The DIPP project has been performed in three Finnish cities 
with a combined annual birth rate of 11,000, representing almost 20% of all 
births in Finland. The project was launched in the city of Turku in Novem-
ber 1994; Oulu joined the study 1 yr later and Tampere 2 yr after that. HLA-
DQ  –  based genetic typing was used to select children positive for DR3-DQ2 
and/or DR4-DQ8 risk haplotypes without protective haplotypes (  6  ). By 
June 6, 2006, 104,111 consecutive newborn infants had been screened, and 
8,026 children with genetic risk continued in the follow up. The DIPP study 
was approved by the local Ethical Committees at the University Hospitals in 
Turku, Oulu, and Tampere. 
  In Turku the children were monitored at 3-mo intervals until 2 yr of 
age and then were monitored twice a year, and in Oulu and Tampere they 
were monitored at 3, 6, 12, 18, and 24 mo and then annually (  40  ). At each 
visit, a venous blood sample was collected from the children without fasting. 
After 30  –  60 min at room temperature, serum was separated and transferred 
to     70  °  C in cryovials within 3 h from the draw. ICA were measured in 
all samples. If a child seroconverted to ICA positivity, IAA, GADA, and 
protein tyrosine phosphatase-like antigen IA-2 (IA-2A) were measured in all 
samples obtained from that child. After seroconversion to autoantibody 
positivity the visits took place at 3-mo intervals in all clinical centers. As of 
January 1, 2003, all four autoantibody types, ICA, GADA, IAA, and IA-2A, 
were measured from all samples drawn as previously described (  32  ). Auto-
antibodies that were present in cord blood and disappeared before 18 mo of 
age were regarded as maternal in origin and such values were excluded from 
the analysis. 
  Between 1997 and 2007, study children with two or more types of au-
toantibodies detected in at least two consecutive serum samples have been 
recruited into a randomized double-blind placebo-controlled trial testing the 
effi   cacy of nasal insulin for preventing type 1 diabetes (http://clinicaltrials
.gov, identifi  er: NCT00223613). The study showed that daily nasal insulin 
administration in an     1 U/kg dose failed to delay diabetes development in 
children with genetic risk and two or more types of autoantibodies (  32  ). 
There were no meaningful diff  erences in serum metabolome components in 
the enrolled children, who comprised roughly half of those eligible, com-
pared with those who did not participate in the prevention trial. 
  Lipidomic analysis.     10-  μ  l serum samples diluted with 10   μ  l of 0.15 M 
NaCl and spiked with a standard mixture containing 10 lipid species 
were extracted with 100   μ  l of a 2:1 mixture of chloroform and methanol. 
phospholipids with the increased risk of type 1 diabetes is the 
enhanced susceptibility of pancreatic      cells to increased oxi-
dative damage (  24  ). Decreased antioxidant capacity of      cells 
caused by low ether phospholipids might so enhance their 
susceptibility to the eff  ects of reactive oxygen species. 
  The appearance of each islet autoantibody was preceded 
by elevated serum concentration of lysoPCs, which are reac-
tive lipid byproducts generated in the hydrolysis of PCs by 
phospholipase A2. These are lipid mediators able to activate 
a range of proinfl  ammatory molecules (  25  ) that function as 
natural adjuvants for the immune system (  26  ). The increased 
levels of lysoPCs observed just a few months before serocon-
version to autoantibody positivity may be consistent with the 
eff  ects of increased oxidative stress associated with, for exam-
ple, a viral infection (  2  ) or some other proinfl  ammatory event. 
  The appearances of autoantibodies against insulin and 
GADA, an enzyme that decarboxylates glutamic acid to 
GABA, were preceded by diminished ketoleucine, elevated 
BCAAs, and elevated glutamic acid. Augmentation of insulin 
secretion by elevated serum BCAAs is well documented (  27  ) 
and high blood levels of BCAAs were previously reported in 
overt type 1 diabetes (  28  ). BCAA and glutamic acid levels are 
restored to normal after the appearance of GADA or IAA 
(  Fig. 6  ).   This raises an intriguing possibility that the initial 
autoimmune response is physiological and aimed at restoring 
the metabolic homeostasis and that the disease may be caused 
by or be at least partially infl  uenced by a defective response 
toward the      cell autoantigens (  29, 30  ). A protective role of 
the diabetes-associated autoantibodies is indirectly supported 
by the observation that the autoantibody titers frequently de-
crease before the presentation of clinical diabetes, which can 
be interpreted as a sign of failing protection (  31  ). 
  Our fi  ndings favor early immunomodulation rather than 
immunosuppression as a preventive therapy for type 1 diabetes, 
with the aim of boosting the benefi  cial components of auto-
immunity. However, despite apparent effi   cacy in animal mod-
els of several immunomodulatory agents, success has been poor 
in human type 1 diabetes prevention trials, including our re-
cent double-blind placebo-controlled nasal insulin study (  32  ). 
Notably, in that study the intervention was conducted in 
children who recently had seroconverted to positivity for two 
or more types of diabetes-associated autoantibodies. Our 
fi  ndings suggest that this period may already be late for such 
a therapeutic intervention and that the preautoimmune period 
could be a more suitable window for disease prevention. 
  Early therapeutic strategies aimed at improving or restor-
ing the metabolic phenotype, e.g., by reestablishing ether 
phospholipid availability or by modulating gut microbial 
composition, might also be of value by preventing      cell de-
struction and delaying progression to overt type 1 diabetes. In 
support of this, administration of docosahexaenoic acid, 
which is known to be selectively targeted to plasmalogens 
(  33  ), has been associated with decreased risk of      cell autoim-
munity and type 1 diabetes (  34, 35  ). 
  One of the strengths of our study is that we used state of 
the art metabolomics technology to examine our large pro-2982 METABOLOME EN ROUTE TO TYPE 1 DIABETES   | Ore  š  ic  ˇ   et  al. 
m/z peaks having more weight than the lower. A similarity value is assigned 
between 0 and 999, with 999 being a perfect match and 750 generally con-
sidered as a reasonable match. We used the conservative cut-off   criterion of 
850 for identifi  cation. Response curves are shown for selected metabolites 
of relevance to the study in Figs. S8 and S9 (available at http://www.jem
.org/cgi/content/full/jem.20081800/DC1). 
  Statistical methods.     R statistical software (http://www.r-project.org/) 
was used for data analyses and visualization. The concentrations were 
compared using the Wilcoxon rank-sum test, with p-values   <  0.05 con-
sidered signifi  cant. To account for multiple comparisons, false discovery 
rate was estimated as the maximum   q  -value (  43  ) in the set of signifi  cant 
diff  erences for each dataset (i.e., lipidomics or metabolomics) and the 
family of hypotheses tested (e.g., diff   erences between progressors and 
nonprogressors in a specifi  c age cohort). False discovery rates were com-
puted using the R package qvalue. Lipid class concentration diff  erences 
between the mean longitudinal profi  les of progressors and nonprogressors 
were tested using linear mixed eff  ects models implemented with the lme 
function in the R package nlme. The fi  xed eff  ects were modeled as con-
stant levels for each group, i.e., for progressors and nonprogressors, and 
the random eff  ects were modeled as constant deviations from these con-
stant group level trajectories. The signifi  cance of the group diff  erences 
was evaluated by the p-value for the fi  xed eff  ect parameter estimate of 
group diff  erences. 
  The fold diff  erence was calculated by dividing the median concentra-
tion in progressors by the median concentration in nonprogressors. If this 
number was less than one, the negative is listed (e.g., 0.75, or a drop of 25% vs. 
nonprogressors, is reported as a     1.3-fold diff  erence). 
  Online supplemental material.     Fig. S1 shows lysoPC levels across all 
1,196 samples measured as a function of sample storage time. Fig. S2 shows 
the total PC concentration in cord serum of progressors and nonprogressors. 
Fig. S3 compares the lipidomes between children with the high-risk HLA 
genotype and those with moderate-risk HLA genotypes. Fig. S4 shows the 
concentrations of ethanolamine plasmalogen detected in a subset of progres-
sors and nonprogressors. Diff  erences in selected metabolite concentrations 
between the progressors to type 1 diabetes and nonprogressors within the 
four 9-mo intervals before disease diagnosis in the progressors are shown in 
Fig. S5. Associations of lysoPC and ether PC with the rate of progression to 
type 1 diabetes are shown in Figs. S6 and S7, respectively. Figs. S8 and S9 
show the selected characteristics of the GCxGC-TOF/MS analytical plat-
form. Table S1 provides an overview of the four analytical runs used to gen-
erate the data for this study. Online supplemental material is available at 
http://www.jem.org/cgi/content/full/jem.20081800/DC1. 
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